Financial reports
10-K
2023 FY
Annual report
8 Mar 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
10-Q
2023 Q1
Quarterly report
5 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
13 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
15 Mar 22
Current reports
8-K
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
8 Mar 24
8-K
Other Events
6 Dec 23
8-K
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
3 Nov 23
8-K
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid
18 Oct 23
8-K
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
2 Oct 23
8-K
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
4 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
5 May 23
8-K
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
1 May 23
8-K
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
27 Apr 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
15 Nov 23
S-3
Shelf registration
3 Nov 23
S-8
Registration of securities for employees
5 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Mar 22
S-8
Registration of securities for employees
15 Mar 22
S-8
Registration of securities for employees
18 Mar 21
424B5
Prospectus supplement for primary offering
20 Nov 20
S-3
Shelf registration
13 Nov 20
424B5
Prospectus supplement for primary offering
26 Aug 20
S-8
Registration of securities for employees
11 Mar 20
Proxies
DEF 14A
Definitive proxy
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEF 14A
Definitive proxy
24 Apr 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEFA14A
Additional proxy soliciting materials
24 Apr 19
DEF 14A
Definitive proxy
24 Apr 19
Other
EFFECT
Notice of effectiveness
16 Nov 23
CORRESP
Correspondence with SEC
13 Nov 23
UPLOAD
Letter from SEC
8 Nov 23
CT ORDER
Confidential treatment order
18 Mar 21
EFFECT
Notice of effectiveness
23 Nov 20
UPLOAD
Letter from SEC
18 Nov 20
CORRESP
Correspondence with SEC
18 Nov 20
EFFECT
Notice of effectiveness
20 Jun 18
CT ORDER
Confidential treatment order
19 Apr 18
EFFECT
Notice of effectiveness
4 May 17
Ownership